Mês: novembro 2016

The Demonization of Vladimir Putin

The Russian media just loves the campaign to demonize Putin   The Saker Nov. 03, 2016   Last May I wrote an article entitled Counter-propaganda, Russian style in which I explained that far from banning or censoring the western anti-Putin/anti-Russia campaign, the Russia media reported about it in meticulous detail.  Half a year later, not only is this still true, but the level of coverage has now sharply increased.  Check out this screenshot from the latest (and most watched) weekly news show: Remember that roughly 80% plus of the audience watching this are strong supporters of President Putin.  You can imagine what they think when they see these reports. The fully understand that the West hates Putin so much precisely because Putin is one of them, a real Russian who cares for the interests of the Russian people.  So when the West demonizes Putin, it is really all the Russian people who are demonized and their conclusion is simple: the West does not hate Putin, the West hates *us*.  As for “Blame it on Putin” – it has now become a real joke. One of the main effects of this kind of demonization is that the Russian public fully understands that there is no way back.  In practical terms, most Russians believe that even if Russia pulled out of Syria, stopped supporting the Donbass or even decided to hand Crimea to...

Ler mais

Hormone replacement therapy could improve physical quality of life for women with MS Researchers note a relationship between HRT and quality of life in women with MS after menopause Last updated: 3rd November 2016   Hormone replacement therapy (HRT) is used to reduce the effects of menopause, when there is a drop in female hormones such as oestrogen. After menopause, healthy women can experience several symptoms, including hot flushes, night sweats, mood swings and reduced sex drive, which reduce their quality of life. Replacement of female hormones may reduce these issues. In this study, investigators at the UCSF MS centre in San Francisco, USA, asked whether quality of life reports from postmenopausal women with MS who were receiving HRT differed from those who were not receiving the therapy. Investigators found 96 reports from women with MS, of whom 61 had received HRT. The reported quality of life scores from the questionnaires completed by these 96 people showed higher scores for physical quality of life in the group who received HRT. This might suggest that hormone replacement therapy could improve physical quality of life for women with MS. The authors of this studies emphasise the need to perform stronger studies to confirm these results, especially because this study was retrospective. Read the full article (external website opens in a new window)   See the...

Ler mais

EM = MS

A new fingolimod-like drug is safe in people with relapsing-remitting MS A phase II trial shows safety and efficacy of amiselimod Last updated: 3rd November 2016 Fingolimod was the first oral tablet approved for people with relapsing-remitting MS. It has shown improved outcomes in comparison with placebo or injectable interferons. However, one side effect of fingolimod is that it can cause the heart to slow down or beat irregularly after the first dose, so recipients have to be monitored in hospital for at least six hours after taking it. As a result, investigators have been looking at ways to reduce the side effects of fingolimod while retaining the beneficial effects. Previous pre-clinical and phase I studies have shown that a new fingolimod-like drug called amiselimod shows less side effects on the heart compared to fingolimod. Therefore, in this study researchers examined the safety and efficacy of amiselimod in a larger number of people with relapsing-remitting MS. Researchers recruited 415 people with MS in 84 centres across Europe and Canada, and followed them for 24 weeks. They found that people who were receiving higher doses of amiselimod had lower disease activity on MRI in comparison with placebo, although lower doses did not show any change in comparison with a placebo. Amiselimod was safe, especially in regard to side effects on the heart rate. Therefore, investigators concluded that this drug merits investigation...

Ler mais

Economia Brasileira

Fuga Contida: BNDES segura JBS   BNDES 26/10/2016 O apoio da BNDESPAR à JBS teve início em 2007, por meio de participação acionária e, posteriormente, debêntures conversíveis. À época, a JBS era uma empresa pouco internacionalizada, com receita de aproximadamente R$ 4 bilhões ao ano. Hoje a JBS é uma empresa brasileira líder global no setor de proteínas, com vendas anuais de R$ 163 bilhões e presença em todos os continentes. A BNDESPAR detém 20,36% do capital social da JBS S/A e é signatária do Acordo de Acionistas da Companhia, que lhe confere certos direitos, dentre eles o direito de veto a reorganizações societárias. Em relação ao cancelamento da reorganização societária da JBS S/A, anunciado nesta quarta-feira (26/10/2016), a BNDESPAR informa que vetou a operação porque não a considerou como a alternativa que melhor atende aos interesses da companhia e de seus acionistas. A BNDESPAR, zelando por seus deveres fiduciários enquanto parte da coletividade de acionistas da companhia, age de forma a proteger os interesses da empresa na qual investiu.  A reorganização proposta, ao prever a transferência da propriedade de ativos que representam aproximadamente 85% da geração do caixa operacional da JBS para uma companhia estrangeira, implicaria na desnacionalização da empresa e alteraria substancialmente os direitos e deveres conferidos a todos os acionistas, com repercussões de diversas naturezas, e submetendo-os a legislação e jurisdição estrangeiras. A BNDESPAR reitera seu...

Ler mais